Ian Stewart (Partner-Los Angeles) and Neil Willner (Associate-White Plains) took a hard look at the U.S. Food and Drug Administration’s (FDA’s) sweeping press release issued on April 2, 2019, by outgoing Commissioner Scott Gottlieb. Covering new steps to advance the FDA’s continued evaluation of potential regulatory pathways for CBD products, the new guidance outlined what the FDA has in store for the industry over the next several months. 

Read the Article.